Oxford Biomedica
2023 Annual Report and Accounts
Oxford, UK - 30 April 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or
"the Company"), a quality and innovation-led cell
and gene therapy CDMO, gives notice that
the 2023 Annual report and accounts is now available on the
"Investors" section of the Group's website at
www.oxb.com. In accordance with Listing rule 9.6.1, the 2023 Annual
report and accounts has also been submitted to the Financial
Conduct Authority for publication through the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Further copies of the 2023 Annual
report and accounts are available from the Company Secretary,
Oxford Biomedica plc, Windrush Court, Transport Way, Oxford, OX4
6LT, United Kingdom (telephone number: +44 (0) 1865 783 000). The
Company confirms that, in compliance with DTR 6.3.5(1A), the
regulated information required under DTR 6.3.5, is available in
unedited full text within the Annual Report available on the
National Storage Mechanism and in compliance with DTR 6.3.5(3) is
available on the Company's website as noted above.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led cell and gene therapy CDMO with a mission to enable
its clients to deliver life changing therapies to patients around
the world.
One of the original pioneers in cell and gene
therapy, the Company has more than 25 years of experience in viral
vectors; the driving force behind the majority of gene therapies.
The Company collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenoviral vectors, and other viral
vector types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on
LinkedIn
and YouTube.
